本帖最后由 老马 于 2012-1-13 21:20 编辑 & e$ Z+ @. ?9 ~6 x r& Z& M1 C
* ^6 U' b% O, ]3 ~爱必妥和阿瓦斯丁的比较
# y4 W0 i1 h) \& o- R: o
" A5 ^0 `8 t6 V
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/& }1 ?& K# }4 L# s* ]5 ]
. U& D- e/ c( ?
" X9 T/ a) l8 A8 F- J8 ghttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
& p: q% ]' w' E! d* r+ z: f==================================================
" P4 W: Y: _7 l* [; |8 q' aOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL): y' K9 d8 t( i1 f9 j9 O( i, N
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. Q; K: D2 b; {! o+ P1 |1 ^
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.( G! A3 B/ i6 X8 ?; o" q0 @9 E
|